United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

cigalah drug store italy - 20’s [20x4g sachets] - powder - combination - n/a

United States - English - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - solaraze® (diclofenac sodium) gel is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. solaraze® (diclofenac sodium) gel is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 350 and/or hyaluronate sodium. solaraze® (diclofenac sodium) gel is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.

United States - English - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 30 mg in 1 g - solaraze® (diclofenac sodium) gel is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. solaraze® (diclofenac sodium) gel is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 350 and/or hyaluronate sodium. solaraze® (diclofenac sodium) gel is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.

United States - English - NLM (National Library of Medicine)

pharmaderm, a division of fougera pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - temovate® gel is a super-high potency cor-ticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. temovate® gel is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

pharmaderm, a division of fougera pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - temovate® scalp application is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 ml/week because of the potential for the drug to suppress the hpa axis. this product is not recommended for use in pediatric patients under 12 years of age. temovate® scalp application is contraindicated in patients with primary infections of the scalp, or in patients who are hypersensitive to clobetasol propionate, other corticosteroids, or any ingredient in this preparation.

United States - English - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - oxiconazole nitrate (unii: rq8ul4c17s) (oxiconazole - unii:c668q9i33j) - oxiconazole 10 mg in 1 g - oxistat® cream and lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, or epidermophyton floccosum. oxistat® cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to malassezia furfur (see dosage and administration and clinical studies). oxistat® cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which oxistat® cream has been shown to be effective rarely occur in children below the age of 12. oxistat® cream and lotion are contraindicated in individuals who have shown hypersensitivity to any of their components.

United States - English - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - methscopolamine bromide (unii: rtn51lk7wl) (methscopolamine - unii:vdr09vtq8u) - methscopolamine bromide 2.5 mg - adjunctive therapy for the treatment of peptic ulcer. methscopolamine bromide has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence or preventing complications. glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. pamine® 2.5 mg/pamine® forte 5 mg is contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs. not applicable.

United States - English - NLM (National Library of Medicine)

pharmaderm, a division of nycomed us inc. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate 0.5 mg in 1 ml